Articles related to Hematology

Final analysis confirms venetoclax plus modified intensive chemotherapy achieves durable remissions with 17.9-month treatment-free intervals in fit elderly AML patients, particularly those with de novo disease.

The analysis demonstrates that periprocedural bleeding rates with factor XI inhibition were comparable to or lower than traditional anticoagulation, with only 0.9% of procedures within 30 days of abelacimab dosing experiencing major bleeding complications.

Cancer research infrastructure faces its most severe funding crisis in over two decades, with institutions forced to choose between maintaining current studies and preserving workforce capacity for future breakthroughs.

Prior to CDC’s Sickle Cell Data Collection program, the actual number of Americans living with sickle cell disease was unknown, with current estimates of 100,000 patients based on systematic data collection efforts now at risk.

Hemoglobin disorders represent the single largest category of genetic disorders in the United States after chromosomal disorders, yet there is no systematic approach to managing them despite excellent guidelines from NHLBI, ASH, and NASCC.

Rates of major bleeding for therapeutic-dose apixaban and dabigatran were similar to those for low-dose aspirin, whereas rates were higher for rivaroxaban.